Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 17, Issue 5, Pages 1219-1225Publisher
SPRINGER
DOI: 10.1245/s10434-010-0976-5
Keywords
-
Funding
- Onyx Pharmaceuticals/Bayer Healthcare Pharmaceuticals
- Sanofi-aventis
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Hepatocellular carcinoma remains a leading cause of cancer death worldwide. There are an increasing number of patients that do not meet traditional criteria for surgical resection as a result of historically poor outcomes. We define these oncologically high-risk patients as those with either one of these risk factors or a combination of them: large (> 5 cm) primary tumors, multinodular disease, and/or major vascular invasion. With appropriate selection and preparation, long-term survival is possible in this subset of patients after resection. This review focuses on the surgical treatment of these high-risk patients, focusing on our own institution's approach and methods as well as reviewing the literature pertinent to the support of our current practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available